Intuitive Surgical has delivered a 35.9% gain over the past three years. With the share price recently closing at US$404.76, the real question for investors is how well that advance lines up with the cash flows the business can generate. With fresh attention on surgical robotics and the company’s role in that market, the focus shifts to whether today’s valuation matches the cash being produced by its installed systems and procedures.
- The 35.9% rise over three years puts real weight on whether Intuitive Surgical’s current market value is fully supported by its cash flow profile.
- Recent commentary on rapid growth in robotic surgical systems highlights potential for higher procedure volumes and system placements, which can influence expectations for future cash generation and the timing of those inflows.
- Prefer to judge Intuitive Surgical on earnings? See why Intuitive Surgical's 45.6x P/E tells a different valuation story.
The stock’s next move may depend on whether the Discounted Cash Flow (DCF) view of Intuitive Surgical’s cash streams lines up with where the market is pricing the shares today.
For a wider view on surgical robotics and related plays, you can also start a focused stock search using 87 robotics and automation stocks.
Does Intuitive Surgical Look Fairly Valued on Cash Flow?
The Discounted Cash Flow (DCF) model here projects what Intuitive Surgical might deliver in future free cash flows and then discounts those amounts back to today. On the latest twelve month numbers, the group generated about $2.7b in free cash flow, which forms the base for a 2 Stage Free Cash Flow to Equity model that assumes growing cash generation rather than a shrinking profile.
Analyst inputs point to higher annual free cash flow in the coming decade, then taper into more moderate expansion in the later stage. This pattern is typical for a mature leader in a focused niche like robotic surgery. Because the projections put Intuitive Surgical's estimated intrinsic value broadly in line with the share price of $404.76, the market is effectively treating that future cash stream as already reflected in today’s quote. Recent reports of rapid growth in robotic surgical systems help explain why investors appear comfortable valuing the stock this way, with future procedures and system placements already priced into expectations. Find out what Intuitive Surgical could be worth using our Discounted Cash Flow (DCF) estimate.
The Intuitive Surgical Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Intuitive Surgical pick up where the valuation question leaves off. They spell out which specific paths for Intuitive Surgical's growth, profitability and earnings would need to play out for the shares to trade meaningfully higher or lower than today, and each scenario links its number to a clear view on how growth, margins and risks might evolve, giving you something concrete to revisit as new information emerges on the Community page.
Community views on Intuitive Surgical split between those who see a high quality business roughly at fair value and those who think expectations already run too hot.
Bull case: 24% undervalued
"ISRG’s robust business model and strong moat come from this recurring revenue, as hospitals must continuously purchase instruments, maintenance services, and software updates..."
Discover why this Narrative puts Intuitive Surgical at 24% undervalued.
Bear case: 25% overvalued
"Bearish analysts expect Intuitive Surgical to experience sustained margin pressure as pricing competition, policy headwinds and new robotic entrants compress returns on its growing installed base..."
Explore why this Narrative puts Intuitive Surgical at 25% overvalued.
One more piece of Intuitive Surgical that could change the story
Cash flows, procedures and systems only tell part of the Intuitive Surgical picture, because the people setting priorities and how they are rewarded can tilt long term outcomes in very different directions. See who runs Intuitive Surgical and how they are paid.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com